In their investigation into the effects of Bifidobacterium infantis—a key Actinobacteria member—on the modulation of inflammatory diseases, Groeger et al. demonstrated that a 6–8-week regimen with Bifidobacterium infantis substantially reduced plasma C-reactive protein (CRP) levels in patients suffering from ulcerative colitis, psoriasis, and chronic fatigue syndrome (36). The gene discussed is CRP; the disease is psoriasis.